NCT03697226View on ClinicalTrials.gov

Study of Topical ABI-1968 in Subjects With Precancerous Cervical Lesions From Human Papillomavirus (HPV) Infection.

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

December 21, 2018

Primary Completion Date

May 26, 2020

Study Completion Date

June 12, 2020

Conditions
HSIL of CervixHSIL, High Grade Squamous Intraepithelial LesionsHigh-Grade Cervical Intraepithelial NeoplasiaHuman Papilloma VirusHIV NegativeCervical CancerCIN - Cervical Intraepithelial NeoplasiaCervical NeoplasmCervical Dysplasia
Interventions
DRUG

Topical ABI-1968

Multiple Doses of Topical ABI-1968 Cream with 4 once weekly doses administered in up to 5 Cohorts

Trial Locations (1)

9301

Research Center, Bloemfontein

Sponsors

Lead Sponsor

Antiva Biosciences
All Listed Sponsors
lead

Antiva Biosciences

INDUSTRY

NCT03697226 - Study of Topical ABI-1968 in Subjects With Precancerous Cervical Lesions From Human Papillomavirus (HPV) Infection. | Biotech Hunter | Biotech Hunter